Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1

NCT05832931 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

362

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Hyperparathyroidism
End-stage Kidney Disease (ESKD)

Interventions

DRUG: PLS240
DRUG: Placebo
DRUG: Open-Label Extension PLS240

Sponsor

Pathalys Pharma

Collaborators

[object Object]